{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T22:56:48Z","timestamp":1775602608524,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02691-8","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T05:44:36Z","timestamp":1743140676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gastrointestinal perforation in general oncology, metastatic colorectal cancer, and metastatic melanoma population"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1007-4997","authenticated-orcid":false,"given":"Arun","family":"Parashar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineet","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varsha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muskan","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"5","key":"2691_CR1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/00004728-199209000-00008","volume":"16","author":"JC Stapakis","year":"1992","unstructured":"Stapakis JC, Thickman D. Diagnosis of pneumoperitoneum: abdominal CT vs. upright chest film. J Comput Assist Tomogr. 1992;16(5):713\u20136.","journal-title":"J Comput Assist Tomogr"},{"issue":"6","key":"2691_CR2","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0033-8389(22)00317-7","volume":"31","author":"GG Ghahremani","year":"1993","unstructured":"Ghahremani GG. Radiologic evaluation of suspected gastrointestinal perforations. Radiol Clin North Am. 1993;31(6):1219\u201334.","journal-title":"Radiol Clin North Am"},{"issue":"4","key":"2691_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s002610000022","volume":"25","author":"V Maniatis","year":"2000","unstructured":"Maniatis V, et al. Perforation of the alimentary tract: evaluation with computed tomography. Abdom Imaging. 2000;25(4):373\u20139.","journal-title":"Abdom Imaging"},{"issue":"4","key":"2691_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jso.10127","volume":"80","author":"Y Kasakura","year":"2002","unstructured":"Kasakura Y, et al. Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. J Surg Oncol. 2002;80(4):181\u20135.","journal-title":"J Surg Oncol"},{"issue":"2B","key":"2691_CR5","first-page":"1209","volume":"22","author":"N Suzaki","year":"2002","unstructured":"Suzaki N, et al. Gastric perforation due to metastasis from adenocarcinoma of the lung. Anticancer Res. 2002;22(2B):1209\u201312.","journal-title":"Anticancer Res"},{"issue":"1","key":"2691_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1006\/gyno.2001.6213","volume":"82","author":"PT Ramirez","year":"2001","unstructured":"Ramirez PT, et al. Sigmoid perforation following radiation therapy in patients with cervical cancer. Gynecol Oncol. 2001;82(1):150\u20135.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"2691_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11894-002-0079-y","volume":"4","author":"MF Bavaro","year":"2002","unstructured":"Bavaro MF. Neutropenic enterocolitis. Curr Gastroenterol Rep. 2002;4(4):297\u2013301.","journal-title":"Curr Gastroenterol Rep"},{"key":"2691_CR8","unstructured":"Hafner J, et al. Intestinal perforation, in StatPearls. 2024: Treasure Island (FL) ineligible companies. Disclosure: Faiz Tuma declares no relevant financial relationships with ineligible companies. Disclosure: Gilles Hoilat declares no relevant financial relationships with ineligible companies. Disclosure: Omar Marar declares no relevant financial relationships with ineligible companies"},{"issue":"1","key":"2691_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/imr.12499","volume":"274","author":"MJ Delano","year":"2016","unstructured":"Delano MJ, Ward PA. The immune system\u2019s role in sepsis progression, resolution, and long-term outcome. Immunol Rev. 2016;274(1):330\u201353.","journal-title":"Immunol Rev"},{"issue":"12","key":"2691_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00520-023-08083-w","volume":"31","author":"DC Guven","year":"2023","unstructured":"Guven DC, et al. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer. 2023;31(12):624.","journal-title":"Support Care Cancer"},{"key":"2691_CR11","doi-asserted-by":"publisher","first-page":"1039121","DOI":"10.3389\/fmolb.2022.1039121","volume":"9","author":"DC Guven","year":"2022","unstructured":"Guven DC, et al. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Mol Biosci. 2022;9:1039121.","journal-title":"Front Mol Biosci"},{"issue":"12","key":"2691_CR12","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/17425255.2021.2029405","volume":"17","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, et al. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin Drug Metab Toxicol. 2021;17(12):1455\u201366.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2691_CR13","doi-asserted-by":"publisher","first-page":"175586","DOI":"10.1016\/j.ejphar.2023.175586","volume":"949","author":"S Ghalehbandi","year":"2023","unstructured":"Ghalehbandi S, et al. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol. 2023;949:175586.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"2691_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","volume":"10","author":"S Hapani","year":"2009","unstructured":"Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10(6):559\u201368.","journal-title":"Lancet Oncol"},{"key":"2691_CR15","first-page":"1","volume":"89","author":"C Mazzeo","year":"2019","unstructured":"Mazzeo C, et al. Metastatic melanoma of the small bowel. Report of a case and review of literature. Ann Ital Chir. 2019;89:1\u20134.","journal-title":"Ann Ital Chir"},{"issue":"4","key":"2691_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1179\/1973947815Y.0000000053","volume":"28","author":"Z Wang","year":"2016","unstructured":"Wang Z, et al. Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials. J Chemother. 2016;28(4):328\u201334.","journal-title":"J Chemother"},{"issue":"26","key":"2691_CR17","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484\u201396.","journal-title":"N Engl J Med"},{"issue":"29","key":"2691_CR18","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1200\/JCO.2012.42.5355","volume":"30","author":"HJ Schmoll","year":"2012","unstructured":"Schmoll HJ, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol. 2012;30(29):3588\u201395.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2691_CR19","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1200\/JCO.2011.38.9650","volume":"30","author":"JA Meyerhardt","year":"2012","unstructured":"Meyerhardt JA, et al. Effectiveness of bevacizumab with first-line combination chemotherapy for medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012;30(6):608\u201315.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2691_CR20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/ajco.12639","volume":"13","author":"B Lee","year":"2017","unstructured":"Lee B, et al. The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: results from a large prospective cohort study. Asia Pac J Clin Oncol. 2017;13(4):314\u201321.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"11","key":"2691_CR21","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480\u201392.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2691_CR22","doi-asserted-by":"publisher","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","volume":"8","author":"CJ Voskens","year":"2013","unstructured":"Voskens CJ, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE. 2013;8(1):e53745.","journal-title":"PLoS ONE"},{"issue":"28","key":"2691_CR23","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol. 2015;33(28):3193\u20138.","journal-title":"J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02691-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02691-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02691-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T01:57:20Z","timestamp":1746151040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02691-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["2691"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02691-8","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest regarding the publication of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"133"}}